Propranolol selectively inhibits cervical cancer cell growth by suppressing the cGMP/PKG pathway - 16/02/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | β-blockers in clinical settings can reduce the rates of progression for some tumors. |
• | The use of integrated bioinformatical analysis combined with experimental verification is an understudied area. |
• | Propranolol can inhibits cervical cancer cell growth by suppressing the cGMP/PKG pathway. |
Abstract |
Aim |
To observe the effect of propranolol in cervical cancer and investigate the mechanism of the effect．
Methods and Results |
We found 5 direct protein targets (DPTs) of propranolol (PRO) by DrugBank5.0 firstly. Next, we analyzed protein-protein interaction (PPI) network and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of PRO DPTs and the result showed that PRO was linked with cGMP/PKG pathway. Then, we recognized the top 38 upexpressed genes of cervical cancer (CC) based original microarray datasets (GSE7803, GSE9750, GSE39001 and GSE63514). Further, we analyzed the biological process with the 38 overexpressed genes by STRING. We found some of overexpressed genes of CC participated in GMP biosynthetic process. Lastly, the function of PRO in CC was validated by MTT assay, Western blotting, flow cytometry and colony formation assay methods. We verified PRO can suppress cGMP/PKG pathway then inhibits CC cell growth.
Conclusion |
The bioinformatical analysis combine with traditional experiment can help us understanding potential molecular mechanism about how PRO acting in CC. This method is a new paradigm which can guide future researches about mechanism in existing diseases and drugs.
Le texte complet de cet article est disponible en PDF.Keywords : Propranolol, Cervical cancer, Bioinformatical analysis, Proliferation, Apoptosis, cGMP-PKG signaling pathway
Plan
Vol 111
P. 1243-1248 - mars 2019 Retour au numéro
Article précédent
- Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 & STEAP1 186-193
- Xuan Chen, Rui Wang, Anji Chen, Yongmei Wang, Yiqin Wang, Jialei Zhou, Rongyue Cao
- Corrigendum to “LINC00657 played oncogenic roles in esophageal squamous cell carcinoma by targeting miR-615-3p and JunB” [Biomed. Pharmacother. 108 (2018) 316–324]
- Sun Yuchen, Wang Jizhao, Pan Shupei, Yang Tian, Sun Xuanzi, Wang Ya, Shi Xiaobo, Zhao Xu, Guo Jing, Zhang Xiaozhi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?